Oncternal Therapeutics
Biotechnology, El Camino Real Ste 300, San Diego, , 92130, California, 12230, United States, 11-50 Employees
Phone Number: +18*********
Who is ONCTERNAL THERAPEUTICS
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on...
Read More
-
Headquarters: 12230 El Camino Real Ste 300, San Diego, California, 92130, United States
-
Date Founded: 2013
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ONCTERNAL THERAPEUTICS
Oncternal Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Oncternal Therapeutics
Answer: Oncternal Therapeutics's headquarters are located at El Camino Real Ste 300, San Diego, , 92130, California, 12230, United States
Answer: Oncternal Therapeutics's phone number is +18*********
Answer: Oncternal Therapeutics's official website is https://oncternal.com
Answer: Oncternal Therapeutics's revenue is $1 Million to $5 Million
Answer: Oncternal Therapeutics's SIC: 2834
Answer: Oncternal Therapeutics's NAICS: 325412
Answer: Oncternal Therapeutics has 11-50 employees
Answer: Oncternal Therapeutics is in Biotechnology
Answer: Oncternal Therapeutics contact info: Phone number: +18********* Website: https://oncternal.com
Answer: Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month